---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-192923"
form_type: "8-K/A"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2022-07-13T23:59:59+00:00"
generated_at: "2026-06-24T16:06:56.766749+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio reports GPH102 preclinical HDR rates up to 40% in sickle cell HSPCs; IND planned mid-2024

## Summary
- GPH102 gene replacement achieved homology directed repair (HDR) rates up to 40% in sickle cell HSPCs and restored adult hemoglobin (HbA) expression.
- Company plans to submit an IND for GPH102 in beta-thalassemia by mid-2024, pending regulatory feedback.
- An encore trial-in-progress poster for GPH101 Phase 1/2 CEDAR trial in sickle cell disease was also presented at ASGCT.
- GPH102 uses UltraHDR platform to replace mutated beta-globin gene, targeting >300 mutations that cause beta-thalassemia.

## SEC filing metadata
- accession: 0001193125-22-192923
- form_type: 8-K/A
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2022-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000119312522192923/0001193125-22-192923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000119312522192923/d379068d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-192923
- JSON: https://secwatch.observer/filing/0001193125-22-192923.json
- Plain text: https://secwatch.observer/filing/0001193125-22-192923.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.